Vincristine

Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).

Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).

Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

• Acute Lymphoblastic Leukemia (ALL)
• Choriocarcinoma
• Chronic Lymphocytic Leukemia
• Ewing's Sarcoma
• Gestational Trophoblastic Neoplasia
• Hepatoblastomas
• Hodgkin's Lymphoma
• Immune Thrombocytopenia (ITP)
• Kaposi's Sarcoma
• Multiple Myeloma (MM)
• Neuroblastoma (NB)
• Non-Hodgkin's Lymphoma (NHL)
• Ovarian germ cell tumour
• Pheochromocytoma
• Relapsed Acute Lymphoblastic Leukemia (ALL)
• Retinoblastoma
• Rhabdomyosarcomas
• Small Cell Lung Cancer (SCLC)
• Wilms' tumor
• Advanced Thymoma